Investor Presentaiton
Globalization Has Entered into Substantial Development Stage
Southeast
Asia
(Marketed) HLX10-Serplulimab
Serplulimab has been approved for 1L ES-SCLC by
Indonesia's food and drug administration (BPOM),
becoming the first marketed China-made PD-1
mAb in Southeast Asia
(Marketed) HLX02-Trastuzumab biosimilar
• HANQUYOU has marketed in 40+ countries and regions, including the EU,
Australia, Argentina, Saudi Arabia, Singapore etc., and is expected to be approved
in the US in 2024. The 2023 ex-China sales of HANQUYOU (revenue reported by
Henlius) has reached RMB 93M
Serplulimab MAA under EMA review
Europe
PD-(L)1 market in Europe
Expected to exceed US$28B1 in 2030
USA
Japan
Serplulimab bridging study in the US is in progress
PD-(L)1 market in the US
Expected to reach US$48.4B1 in 2030
Explore potential market with unmet medical needs
PD-(L)1 market in Japan
Expected to exceed US$8.4B1 in 2030
.
•
HLX11-Pertuzumab biosimilar
MRCT has enrolled 908 patients
globally, expected to be the first
approved Pertuzumab biosimilar
in the US and Europe
As the 2023 sales of the originator
drug was over US$3.95B2,
HLX11 will have a promising global
market prospect by licensing
collaboration with ORGANON
HLX14- Denosumab biosimilar
MRCT has enrolled 514 patients
globally, and HLX14 is expected
to file BLA in the US in 2024
As the originator drug achieved
over US$6.16B2 sales in 2023,
HLX14 will have a promising global
market prospect by licensing
collaboration with ORGANON
8
1.Data source: IQVIA MIDAS AUDITED VALUE, the European market includes EU and the UK
2. From the annual report of the originator drug owners
O 2024 Henlius.
2 HenliusView entire presentation